All In Biotech

Drug Trial Radar · NCT04231968

A Study of AK0529 in Chinese Infants Hospitalized With RSV

A Randomized, Double-blind, Placebo-controlled, 2-part Study of Orally Administered AK0529 to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Antiviral Effect of Multiple Doses in Hospitalized Infants With Respiratory Syncytial Virus Infection

Last checked: Nov 20, 2026Latest source record: Feb 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 311 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

311

Actual

Start

Sep 22, 2020

Primary completion

Jan 21, 2022

Study completion Feb 2, 2022

Sponsor

Sponsor type
Industry
First posted
Jan 18, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 1 month, up to 24 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, multicenter, phase III study to be conducted in infants hospitalized with RSV infection in China. The main objectives of this study are to investigate the efficacy and safety of AK0529 in Chinese infants.

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

  • AK0529Drug

    AK0529 capsule will be orally administered at the twice-daily dosing levels of 10 mg, 20 mg, or 40 mg for five days based on the patient's weight.

  • Matching placebo of AK0529Drug

    The placebo capsule was made with the same smell and appearance as AK0529 but without the active ingredients and will be orally administered per the same treatment schedule as those in the experimental arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinically significant change from baseline in bronchiolitis score on Day 3Time frame: From Baseline (Pre-dose on Day 1) to Day 3 (48 hours)

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Children's Hospital

    Beijing, China

  • Peking University Third Hospital

    Beijing, China

  • The First Bethune Hospital of Jilin University

    Changchun, China

  • Hunan Provincial People's Hospital

    Changsha, China

  • West China Women's and Children's Hospital

    Chengdu, China

  • Children's Hospital of Chongqing Medical University

    Chongqing, China

  • Guangzhou Women and Children's Medical Center

    Guangzhou, China

  • The Children's Hospital of Zhejiang University School of Medicine

    Hangzhou, China

  • Liaocheng People's Hospital

    Liaocheng, China

  • Jiangxi Provincial Children's Hospital

    Nanchang, China

  • Children's Hospital of Nanjing Medical University

    Nanjing, China

  • Jiangsu Province Hospital

    Nanjing, China

  • The First Affiliated Hospital of Guangxi Medical University

    Nanjing, China

  • Hainan Third People's Hospital

    Sanya, China

  • Children's Hospital of Shanghai

    Shanghai, China

  • Shanghai Children's Medical Center

    Shanghai, China

  • Shengjing Hospital of China Medical University

    Shengyang, China

  • Shenzhen Children's Hospital

    Shenzhen, China

  • Children's Hospital of Soochow University

    Suzhou, China

  • Tianjin Children's Hospital

    Tianjin, China

  • The Second Affiliated Hospital and Yuying Children's Hospital of WMU

    Wenzhou, China

  • Wuhan Children's Hospital

    Wuhan, China

  • Wuxi Children's Hospital

    Wuxi, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, China

  • Xiamen Maternity and Child Healthcare Hospital

    Xiamen, China

  • Henan Children's Hospital

    Zhengzhou, China

  • The Third Affiliated Hospital of Zhengzhou University

    Zhengzhou, China

  • Boai Hospital of Zhongshan

    Zhongshan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.